IDEAYA Biosciences, Inc. (NASDAQ:IDYA) to Post FY2027 Earnings of ($0.58) Per Share, Wedbush Forecasts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Wedbush lowered their FY2027 EPS estimates for shares of IDEAYA Biosciences in a report issued on Monday, July 8th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings per share of ($0.58) for the year, down from their previous forecast of $0.36. Wedbush currently has a “Outperform” rating and a $56.00 price objective on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($2.37) per share. Wedbush also issued estimates for IDEAYA Biosciences’ FY2028 earnings at $2.94 EPS.

Several other research analysts have also weighed in on IDYA. The Goldman Sachs Group cut their price objective on shares of IDEAYA Biosciences from $53.00 to $46.00 and set a “buy” rating on the stock in a report on Monday, May 13th. Stifel Nicolaus reiterated a “buy” rating and set a $63.00 price objective on shares of IDEAYA Biosciences in a report on Monday. Oppenheimer increased their price objective on shares of IDEAYA Biosciences from $53.00 to $60.00 and gave the stock an “outperform” rating in a report on Monday. Citigroup raised their price target on shares of IDEAYA Biosciences from $40.00 to $60.00 and gave the company a “buy” rating in a report on Thursday, March 21st. Finally, BTIG Research raised their price target on shares of IDEAYA Biosciences from $55.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday. Fourteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $52.08.

IDEAYA Biosciences Price Performance

IDEAYA Biosciences stock opened at $39.62 on Thursday. IDEAYA Biosciences has a 12-month low of $20.90 and a 12-month high of $47.74. The stock has a market capitalization of $3.00 billion, a P/E ratio of -19.71 and a beta of 0.86. The firm’s 50-day moving average is $38.33 and its two-hundred day moving average is $40.70.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). IDEAYA Biosciences had a negative return on equity of 20.09% and a negative net margin of 483.05%. During the same quarter last year, the firm earned ($0.49) EPS. The company’s revenue for the quarter was down 100.0% compared to the same quarter last year.

Insider Buying and Selling at IDEAYA Biosciences

In other IDEAYA Biosciences news, insider Michael Anthony White sold 28,500 shares of the stock in a transaction that occurred on Wednesday, May 29th. The shares were sold at an average price of $36.24, for a total value of $1,032,840.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Yujiro S. Hata sold 56,711 shares of IDEAYA Biosciences stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $41.61, for a total value of $2,359,744.71. Following the completion of the sale, the chief executive officer now owns 677,887 shares in the company, valued at $28,206,878.07. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Anthony White sold 28,500 shares of IDEAYA Biosciences stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $36.24, for a total transaction of $1,032,840.00. The disclosure for this sale can be found here. Insiders sold 119,644 shares of company stock valued at $4,832,228 over the last 90 days. 3.50% of the stock is owned by corporate insiders.

Institutional Trading of IDEAYA Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Covestor Ltd increased its stake in IDEAYA Biosciences by 9,225.0% during the first quarter. Covestor Ltd now owns 1,119 shares of the company’s stock valued at $49,000 after purchasing an additional 1,107 shares during the last quarter. Comerica Bank increased its stake in IDEAYA Biosciences by 723.5% during the first quarter. Comerica Bank now owns 1,507 shares of the company’s stock valued at $66,000 after purchasing an additional 1,324 shares during the last quarter. JTC Employer Solutions Trustee Ltd acquired a new position in shares of IDEAYA Biosciences during the first quarter valued at $67,000. SG Americas Securities LLC acquired a new position in shares of IDEAYA Biosciences during the first quarter valued at $101,000. Finally, AJOVista LLC acquired a new position in shares of IDEAYA Biosciences during the fourth quarter valued at $99,000. Institutional investors own 98.29% of the company’s stock.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.